MM19-01

Main Content

Impact of induction therapy with bortezomib, lenalidomide and dexamethasone vs. bortezomib, cyclophosphamide and dexamethasone on outcomes in patients with multiple myeloma undergoing stem cell transplantation.

Study #: MM19-01

Study Status: Published

Presentation(s)

2020, ASH (Poster)

Impact of induction therapy with VRD versus VCD on outcomes in patients with multiple myeloma in partial response or better undergoing upfront autologous stem cell transplantation.

Citation

Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, Anderson LD Jr, Aljurf M, Banerjee R, Bashey A, Battiwalla M, Beitinjaneh A, Chakraborty R, Chhabra S, Dhakal B, Dholaria B, Hashmi S, Janakiram M, Lee C, Lekakis L, Murthy HS, Parrondo R, Wangjam T, Usmani S, Shah N, Qazilbash M, D'Souza A.

Transplantation and Cellular Therapy. 2022, Feb 03: 8(2): 8(2):e1-83.e9. doi: 10.1016/j.jtct.2021.10.022. Epub 2021, Nov 12. PMCID:PMC8900987.

PubMed

PMID: 34781066

Abstract